

Patent Update

Suven Life Sciences secures Product Patents in South Korea

HYDERABAD, INDIA (Feb 04, 2020) – Suven Life Sciences Ltd (Suven) secures two (2) product patents from South Korea (10-2039585 and 10-2040639) for combination of H3 inverse agonist with Donepezil and Donepezil + Memantine respectively for the treatment of disorders associated with Neurodegenerative diseases and Patent is valid through 2037.

The granted claims of the patents include the class of selective H3 inverse agonists and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia etc.

Disclaimer and Risk Statement: Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited